Souhaitez-vous accéder aux communiqués récents ?

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organization and drive...

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...

Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The global life sciences analytics market was valued at 11.10 billion in 2024 and is expected to reach US$ 23.17 billion by 2033, growing at a CAGR of...

TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced...

PRINCETON, N.J. and SHANGHAI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- QuantX Biosciences, Inc., a computationally driven drug discovery and development company using advanced modeling and high-performance...

Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le...

The US and Japan granted breakthrough therapy/orphan status to rilzabrutinib for wAIHA, a rare blood disorder marked by the destruction of red blood cells

Chicago, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The global chemotherapy-induced peripheral neuropathy Market is estimated to grow at a CAGR of 5.16% during the forecast period 2022-2030 ...

Dublin, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The "Coxsackievirus Infections Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" report has been added to ...

The global Anti-obesity Drugs market is projected to grow at a CAGR of 24.2% to reach US$195.99 billion by 2036.